ClinicalTrials.gg
CompletedNCT03814590Updated Aug 5, 2022Results posted

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

A Phase 1/2 interventional study of RSV Vaccine (GSK3844766A) unadjuvanted low dose and RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 21 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,053
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.

Enrollment
13th of 40
1,053 · median 642
Started
2019
with 5 others
Phase 1/2
4 of 40
1 open now
Registered
11th of 40
by date

Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 13th largest by enrollment, is one of 6 that started in 2019, is one of 4 in phase 1/2, and was the 11th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, reactogenicity and immune responses of two doses of the investigational RSV vaccines (with different formulations), when administered intramuscularly (IM) according to a 0, 2 month schedule, in older adults aged 60 to 80 years.

As the investigational vaccines have not yet been tested in humans before, the study will first assess the safety, reactogenicity and immune responses in young adults aged 18 to 40 years. The study will thus be conducted in 2 parts (Part A and Part B).

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus (RSV)
  • Vaccine
  • Safety
  • Reactogenicity
  • Immunogenicity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all subjects:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written obtained from the subject prior to performing any study specific procedure.

For Part A:

  • A male or female between, and including, 18 and 40 years of age at the time of the first vaccination.

For Part B:

  • A male or female between, and including, 60 and 80 years of age at the time of the first vaccination.
  • Subjects with residence status allowing free mixing with general community or in an assisted-living facility that provides minimal assistance, such that the subject is primarily responsible for self-care and activities of daily living.

Exclusion criteria

Exclusion Criteria:

For all subjects:

  • Use of any or non-registered product other than the study vaccine during the period starting 30 days before the first dose of study vaccine, or planned use during the study period.
  • Any medical condition that in the judgment of the investigator would make IM injection unsafe.
  • Chronic administration of or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For , this will mean prednisone (≥ 20 mg/day, or equivalent). Inhaled and topical steroids are allowed.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 30 days after each study vaccination.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness. Patients with chronic stable conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study.
  • Any other condition (e.g. or severe respiratory condition) that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • History of any neurological disorders or seizures.
  • Acute disease and/or fever at the time of enrolment.
  • Acute or chronic, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by the investigator based on medical history, physical examination or laboratory screening tests.
  • Hepatomegaly, right upper quadrant abdominal pain or tenderness.
  • Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccine or planned administration during the study period.
  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Previous vaccination with an RSV vaccine.
  • Lymphoproliferative disorder and within 5 years.
  • > 40 kg/m².
  • Planned move to a location that will prohibit participating in the trial until study end.
  • At screening: Hematology parameters (complete blood cell count [red blood cells, white blood cells], white blood cells differential count [lymphocytes, neutrophils and eosinophils], count or level) and/or biochemistry parameters (creatinine, blood urea nitrogen or liver enzymes [ or aspartate aminotransferase]) outside the normal laboratory ranges, unless the laboratory abnormalities are considered not clinically significant by the investigator.

For Part A:

  • Pregnant or lactating female.
  • Female subjects of , except if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

For Part B:

  • Known previous administration of a vaccine containing MPL, QS-21 and/or MF59 (e.g. GSK Biologicals' vaccine against human papillomavirus infection marketed as Cervarix, GSK Biologicals' Herpes Zoster vaccine marketed as Shingrix, an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine [HZ/su], or MF59 adjuvanted influenza vaccines [e.g. Fluad]).
  • Planned administration of GSK Biologicals' Herpes Zoster vaccine marketed as Shingrix or an adjuvanted recombinant varicella zoster virus envelope gE subunit vaccine [HZ/su] within 180 days after the second dose of the study vaccine.
  • Bedridden subjects.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,053 participants (actual)

Study arms

  • Experimental
    Group Low Dose_PLAIN_A

    Subjects in Part A, aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) unadjuvanted low dose

  • Experimental
    Group Medium Dose_PLAIN_A

    Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) unadjuvanted medium dose

  • Experimental
    Group High Dose_PLAIN_A

    Subjects in Part A aged 18-40 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) unadjuvanted high dose

  • Placebo comparator
    Group Placebo_A

    Subjects in Part A aged 18-40 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Drug: Placebo (Saline solution)

  • Experimental
    Group Low Dose_PLAIN_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted low dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) unadjuvanted low dose

  • Experimental
    Group Low Dose_AS01E_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E

  • Experimental
    Group Low Dose_AS01B_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B

  • Experimental
    Group Medium Dose_PLAIN_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted medium dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) unadjuvanted medium dose

  • Experimental
    Group Medium Dose_AS01E_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E

  • Experimental
    Group Medium Dose_AS01B_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B

  • Experimental
    Group High Dose_PLAIN_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of RSV Vaccine (GSK3844766A) unadjuvanted high dose, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) unadjuvanted high dose

  • Experimental
    Group High Dose_AS01E_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E

  • Experimental
    Group High Dose_AS01B_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of the RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Biological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B

  • Placebo comparator
    Group Placebo_B

    Subjects in Part B aged 60-80 years, receiving 2 doses of placebo (saline solution) control, on a 0, 2 Months schedule, by IM injection into the deltoid region of the arm.

    Drug: Placebo (Saline solution)

Interventions

  • BiologicalRSV Vaccine (GSK3844766A) unadjuvanted low dose

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm

  • BiologicalRSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

  • BiologicalRSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm

  • BiologicalRSV Vaccine (GSK3844766A) unadjuvanted medium dose

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

  • BiologicalRSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

  • BiologicalRSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

  • BiologicalRSV Vaccine (GSK3844766A) unadjuvanted high dose

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

  • BiologicalRSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm

  • BiologicalRSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

  • DrugPlacebo (Saline solution)

    Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose

    Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)

    Time frame: During a 7-day follow-up period after first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)

  2. Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose

    Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)

    Time frame: During a 7-day follow-up period after second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)

  3. Number of Subjects With Any Solicited General Symptom After First Vaccination Dose

    Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.

    Time frame: During a 7-day follow-up period after the first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)

  4. Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose

    Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.

    Time frame: During a 7-day follow-up period after the second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)

  5. Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination dose (across doses)

  6. Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups)

    Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

    Time frame: At baseline and at 7 days after the first vaccine dose (Day 8)

  7. Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups)

    Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

    Time frame: At baseline and at 7 days after the first vaccine dose (Day 8)

  8. Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups)

    Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

    Time frame: At baseline and at 7 days after the second vaccine dose (Day 68)

  9. Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups)

    Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

    Time frame: At baseline and at 7 days after the second vaccine dose (Day 68)

  10. Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination

    A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

    Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first dose of vaccination

  11. Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination

    A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

    Time frame: During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second dose of vaccination

  12. Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

    Time frame: From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)

  13. Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)

Secondary outcomes

  1. Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups

    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: From Day 1 up to the end of follow-up period (Month 14)

  2. Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From Day 1 up to the end of follow-up period (Month 14)

  3. Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups

    The number of subjects with at least one RTI case was provided by group. Reported categories are RSV+ (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab) and RSV- (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab).

    Time frame: During the RSV season (from October 2019 to March 2020)

  4. Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A

    Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).

    Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)

  5. Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations

    The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).

    Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)

  6. Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers

    Among markers expressed were interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations. Reported statistics at each time point during which blood sample were collected for cell-mediated immunity, are geometric mean and inter-quartile range.

    Time frame: At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)

07

Results

Posted Mar 23, 2022

Participant flow

Participant flow — Overall Study
MilestoneLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Started1212121210197100101101100103100101101
Completed12101112100929795101951001009798
Not completed02101536053043
Withdrew: Adverse event00000111001030
Withdrew: Lost to follow-up02101111001001
Withdrew: Consent withdrawal, due to covid-19 but not due to an adverse event00000000010000
Withdrew: Consent withdrawal, not due to covid-19 and not due to an adverse event00000312031012
Withdrew: Migrated / moved from the study area00000001010000
Withdrew: Unknown reason00000001000000

Outcome measures

PrimaryNumber of Subjects With Any Solicited Local Symptoms After First Vaccination Dose

Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)

Time frame:
During a 7-day follow-up period after first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Erythema01000125691615181
Pain176095145457567863764
Swelling000000277610790
PrimaryNumber of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose

Assessed solicited local AEs at injection site are pain, erythema and swelling. Any erythema/swelling was scored as injection site erythema/swelling with a diameter larger than (\>) 20 millimeters (mm)

Time frame:
During a 7-day follow-up period after second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Erythema00001023371614120
Pain57811818233448475856594
Swelling0000012336107100
PrimaryNumber of Subjects With Any Solicited General Symptom After First Vaccination Dose

Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.

Time frame:
During a 7-day follow-up period after the first vaccination dose (i.e., on the day of vaccination [at Day 1] and 6 subsequent days)
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited General Symptom After First Vaccination Dose
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Arthralgia00007407126159177
Fatigue451622112426282130294916
Fever00001001313310
Gastrointestinal symptoms121188108891371310
Headache243287132012172827288
Myalgia01104319861912185
Shivering0201112653128161
PrimaryNumber of Subjects With Any Solicited General Symptom After Second Vaccination Dose

Assessed solicited general symptoms include arthralgia, fatigue, fever \[defined as temperature equal to or above 38.0 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhea and/or abdominal pain\], headache, myalgia and shivering.

Time frame:
During a 7-day follow-up period after the second vaccination dose (i.e., on the day of vaccination [at Day 61] and 6 subsequent days)
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited General Symptom After Second Vaccination Dose
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Arthralgia000014288102111134
Fatigue324516111324222435353416
Fever00000003114630
Gastrointestinal symptoms112242775711796
Headache223311981518103326189
Myalgia000002369111912182
Shivering0000000934141292
PrimaryNumber of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During a 30-day follow-up period (i.e., on the day of vaccination and 29 subsequent days) after any vaccination dose (across doses)
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Number of Subjects With Any Unsolicited Adverse Events (AEs) After Any Vaccination Dose244634283040293639344333
PrimaryNumber of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups)

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

Time frame:
At baseline and at 7 days after the first vaccine dose (Day 8)
Reported as:
Count of participants · Participants
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part A Groups)
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A Group
ALT-WITHIN-WITHIN12121112
AST-WITHIN-WITHIN11121111
AST-ABOVE-WITHIN1001
Basophils-WITHIN-WITHIN12121112
Creatinine-BELOW-BELOW0001
Creatinine-BELOW-WITHIN1200
Creatinine-WITHIN-WITHIN1191111
Creatinine-ABOVE-ABOVE0100
Eosinophils-BELOW-BELOW0100
Eosinophils-BELOW-WITHIN0010
Eosinophils-WITHIN-WITHIN11101012
Eosinophils-ABOVE-WITHIN1100
Erythrocytes-BELOW-WITHIN1001
Erythrocytes-WITHIN-WITHIN11111111
Erythrocytes-ABOVE-WITHIN0100
Hemoglobin-BELOW-BELOW0001
Hemoglobin-BELOW-WITHIN1000
Hemoglobin-WITHIN-WITHIN11121111
Lymphocytes-BELOW-WITHIN0101
Lymphocytes-WITHIN-WITHIN12111111
Monocytes-BELOW-WITHIN0100
Monocytes-WITHIN-WITHIN12111112
Neutrophis-BELOW-BELOW0010
Neutrophils-BELOW-WITHIN2100
Neutrophils-WITHIN-WITHIN8111012
Neutrophils-ABOVE-WITHIN1000
Neutrophils-ABOVE-ABOVE1000
Platelets-WITHIN-WITHIN12121112
Urea Nitrogen-WITHIN-BELOW0001
Urea Nitrogen-WITHIN-WITHIN12121111
Uric Acid-BELOW-WITHIN1000
Uric Acid-WITHIN-WITHIN11121112
White Blood Cells-BELOW-BELOW0100
White Blood Cells-BELOW-WITHIN2011
White Blood Cells-WITHIN-WITHIN8111011
White Blood Cells-ABOVE-WITHIN1000
White Blood Cells-ABOVE-ABOVE1000
PrimaryNumber of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups)

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 1 (pre-vaccination dose 1=baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

Time frame:
At baseline and at 7 days after the first vaccine dose (Day 8)
Reported as:
Count of participants · Participants
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After First Vaccine Dose (Part B Groups)
ParticipantsLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
ALT-WITHIN-UNKNOWN0001000011
ALT-WITHIN-WITHIN9997989798100100949898
ALT-WITHIN-ABOVE1010000101
ALT-ABOVE-WITHIN0000200200
ALT-ABOVE-ABOVE1002003321
AST-WITHIN-UNKNOWN0001012111
AST-WITHIN-WITHIN100979898999897979899
AST-WITHIN-ABOVE1011000011
AST-ABOVE-WITHIN0000111100
AST-ABOVE-ABOVE0000003110
Basophils-WITHIN-UNKNOWN0101420000
Basophils-WITHIN-WITHIN1009699999698103100101100
Basophils-WITHIN-ABOVE1000000001
Creatinine-BELOW-BELOW0543401320
Creatinine-BELOW-WITHIN1320123231
Creatinine-WITHIN-UNKNOWN0000000011
Creatinine-WITHIN-BELOW1111111153
Creatinine-WITHIN-WITHIN92838992929393908895
Creatinine-WITHIN-ABOVE1121213100
Creatinine-ABOVE-UNKNOWN0001000000
Creatinine-ABOVE-WITHIN2001010100
Creatinine-ABOVE-ABOVE4411022221
Eosinophils-BELOW-BELOW2340353422
Eosinophils-BELOW-WITHIN5313125231
Eosinophils-BELOW-ABOVE0001001000
Eosinophils-WITHIN-UNKNOWN0101420000
Eosinophils-WITHIN-BELOW3122113535
Eosinophils-WITHIN-WITHIN85868891898888869090
Eosinophils-WITHIN-ABOVE2100110111
Eosinophils-ABOVE-WITHIN2141000002
Eosinophils-ABOVE-ABOVE2101113220
Erythrocytes-BELOW-BELOW4301432112
Erythrocytes-BELOW-WITHIN1110010021
Erythrocytes-WITHIN-UNKNOWN0101320000
Erythrocytes-WITHIN-BELOW5100332141
Erythrocytes-WITHIN-WITHIN89899598888995969394
Erythrocytes-WITHIN-ABOVE1010100100
Erythrocytes-ABOVE-WITHIN0110102110
Erythrocytes-ABOVE-ABOVE1110022003
Hemoglobin-BELOW-UNKNOWN0100000000
Hemoglobin-BELOW-BELOW9514744351
Hemoglobin-BELOW-WITHIN1201020141
Hemoglobin-WITHIN-UNKNOWN0001320000
Hemoglobin-WITHIN-BELOW4311122352
Hemoglobin-WITHIN-WITHIN87839691889096908695
Hemoglobin-WITHIN-ABOVE0000000201
Hemoglobin-ABOVE-WITHIN0211001011
Hemoglobin-ABOVE-ABOVE0101100100
Lymphocytes-BELOW-BELOW1001012101
Lymphocytes-BELOW-WITHIN1202322110
Lymphocytes-WITHIN-UNKNOWN0101420000
Lymphocytes-WITHIN-BELOW0101103002
Lymphocytes-WITHIN-WITHIN999299949094969810098
Lymphocytes-WITHIN-ABOVE0001110000
Lymphocytes-ABOVE-WITHIN0100000000
Lymphocytes-ABOVE-ABOVE0000100000
Monocytes-BELOW-UNKNOWN0000010000
Monocytes-BELOW-BELOW1100120520
Monocytes-BELOW-WITHIN3132015123
Monocytes-WITHIN-UNKNOWN0101410000
Monocytes-WITHIN-BELOW5020132143
Monocytes-WITHIN-WITHIN91949497929196929395
Monocytes-WITHIN-ABOVE1000210100
Neutrophils-BELOW-BELOW1021112015
Neutrophils-BELOW-WITHIN0113031112
Neutrophils-WITHIN-UNKNOWN0101420000
Neutrophils-WITHIN-BELOW2112220110
Neutrophils-WITHIN-WITHIN98949589928898969693
Neutrophils-WITHIN-ABOVE0001120120
Neutrophils-ABOVE-WITHIN0002022101
Neutrophils-ABOVE-ABOVE0001000000
Platelets-UNKNOWN-UNKNOWN0010000000
Platelets-BELOW-BELOW3121120112
Platelets-BELOW-WITHIN0010112010
Platelets-WITHIN-UNKNOWN1103632010
Platelets-WITHIN-BELOW0101101000
Platelets-WITHIN-WITHIN96949493909397969696
Platelets-WITHIN-ABOVE0010101110
Platelets-ABOVE-WITHIN0001000100
Platelets-ABOVE-ABOVE1001010113
Urea Nitrogen-BELOW-BELOW0001001000
Urea Nitrogen-WITHIN-UNKNOWN0001000011
Urea Nitrogen-WITHIN-BELOW0000001000
Urea Nitrogen-WITHIN-WITHIN97969595979396969898
Urea Nitrogen-WITHIN-ABOVE1132102211
Urea Nitrogen-ABOVE-WITHIN0010252201
Urea Nitrogen-ABOVE-ABOVE3001021010
Uric Acid-BELOW-BELOW1003015322
Uric Acid-BELOW-WITHIN0200012101
Uric Acid-WITHIN-UNKNOWN0001000011
Uric Acid-WITHIN-BELOW0000021201
Uric Acid-WITHIN-WITHIN94919693989089889589
Uric Acid-WITHIN-ABOVE1302113103
Uric Acid-ABOVE-WITHIN2110122232
Uric Acid-ABOVE-ABOVE3021031302
White Blood Cells-BELOW-UNKNOWN0000010000
White Blood Cells-BELOW-BELOW1022213014
White Blood Cells-BELOW-WITHIN2124132446
White Blood Cells-WITHIN-UNKNOWN0101410000
White Blood Cells-WITHIN-BELOW2232131101
White Blood Cells-WITHIN-WITHIN94919187898795919390
White Blood Cells-WITHIN-ABOVE0111120220
White Blood Cells-ABOVE-WITHIN1001121210
White Blood Cells-ABOVE-ABOVE1102101000
PrimaryNumber of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups)

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

Time frame:
At baseline and at 7 days after the second vaccine dose (Day 68)
Reported as:
Count of participants · Participants
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part A Groups)
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A Group
ALT-WITHIN-WITHIN11101012
ALT-WITHIN-ABOVE1000
ALT-ABOVE-WITHIN0010
AST-WITHIN-WITHIN10101112
AST-WITHIN-ABOVE1000
AST-ABOVE-ABOVE1000
Basophils-UNKNOWN-WITHIN1000
Basophils-WITHIN-WITHIN11101112
Creatinine-BELOW-BELOW0001
Creatinine-WITHIN-WITHIN1271110
Creatinine-WITHIN-ABOVE0200
Creatinine-ABOVE-WITHIN0001
Creatinine-ABOVE-ABOVE0100
Eosinophils-UNKNOWN-WITHIN1000
Eosinophils-BELOW-BELOW0010
Eosinophils-BELOW-WITHIN0100
Eosinophils-WITHIN-BELOW1010
Eosinophils-WITHIN-WITHIN109812
Eosinophils-WITHIN-ABOVE0010
Erythrocytes-UNKNOWN-BELOW1000
Erythrocytes-WITHIN-BELOW1000
Erythrocytes-WITHIN-WITHIN1091012
Erythrocytes-WITHIN-ABOVE0010
Erythrocytes-ABOVE-ABOVE0100
Hemoglobin-UNKNOWN-BELOW1000
Hemoglobin-BELOW-WITHIN0010
Hemoglobin-WITHIN-WITHIN1110912
Hemoglobin-WITHIN-ABOVE0010
Lymphocytes-UNKNOWN-WITHIN1000
Lymphocytes-BELOW-WITHIN0001
Lymphocytes-WITHIN-WITHIN11101111
Monocytes-UNKNOWN-WITHIN1000
Monocytes-BELOW-WITHIN0010
Monocytes-WITHIN-WITHIN11101012
Neutrophils-UNKNOWN-WITHIN1000
Neutrophils-BELOW-BELOW0010
Neutrophils-BELOW-WITHIN1000
Neutrophils-WITHIN-BELOW1000
Neutrophils-WITHIN-WITHIN9101012
Platelets-UNKNOWN-WITHIN1100
Platelets-WITHIN-WITHIN1181112
Platelets-ABOVE-WITHIN0100
Urea Nitrogen-WITHIN-WITHIN12101112
Uric Acid-BELOW-WITHIN1000
Uric Acid-WITHIN-WITHIN11101112
White Blood Cells-UNKNOWN-WITHIN1000
White Blood Cells-BELOW-BELOW1010
White Blood Cells-BELOW-WITHIN1000
White Blood Cells-WITHIN-BELOW1000
White Blood Cells-WITHIN-WITHIN7101012
White Blood Cells-ABOVE-WITHIN1000
PrimaryNumber of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups)

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, white blood cells. Biochemical laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine, urea nitrogen and uric acid. Categories reported when comparing Day 61 (pre-vaccination dose 2=baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Ranges level being classified as unknown, below, within or above the normal ranges.

Time frame:
At baseline and at 7 days after the second vaccine dose (Day 68)
Reported as:
Count of participants · Participants
Number of Subjects Presenting Change From Baseline in Hematology and Biochemistry With Respect of Normal Laboratory Ranges, After Second Vaccine Dose (Part B Groups)
ParticipantsLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
ALT-UNKNOWN-WITHIN1001011120
ALT-WITHIN-UNKNOWN0000000001
ALT-WITHIN-WITHIN93949593949495919096
ALT-WITHIN-ABOVE2000220210
ALT-ABOVE-WITHIN1001101220
ALT-ABOVE-ABOVE0001101122
AST-UNKNOWN-WITHIN1001011120
AST-WITHIN-UNKNOWN0000000001
AST-WITHIN-WITHIN94939593979495939297
AST-WITHIN-ABOVE2001020210
AST-ABOVE-WITHIN0100100010
AST-ABOVE-ABOVE0001002111
Basophils-UNKNOWN-WITHIN1010222121
Basophils-WITHIN-UNKNOWN1000110001
Basophils-WITHIN-WITHIN95949496959496969597
Creatinine-UNKNOWN-BELOW0000000010
Creatinine-UNKNOWN-WITHIN1001010110
Creatinine-UNKNOWN-ABOVE0000001000
Creatinine-BELOW-UNKNOWN0000000001
Creatinine-BELOW-BELOW0422412310
Creatinine-BELOW-WITHIN3211001360
Creatinine-WITHIN-BELOW1222332110
Creatinine-WITHIN-WITHIN83818687889088868396
Creatinine-WITHIN-ABOVE3020113131
Creatinine-ABOVE-WITHIN2202101000
Creatinine-ABOVE-ABOVE4321110211
Eosinophils-UNKNOWN-WITHIN1010212121
Eosinophils-UNKNOWN-ABOVE0000010000
Eosinophils-BELOW-UNKNOWN1000000000
Eosinophils-BELOW-BELOW3242341143
Eosinophils-BELOW-WITHIN3354515725
Eosinophils-WITHIN-UNKNOWN0000110001
Eosinophils-WITHIN-BELOW2246316130
Eosinophils-WITHIN-WITHIN82857879798378838387
Eosinophils-WITHIN-ABOVE2002131310
Eosinophils-ABOVE-WITHIN1122014102
Eosinophils-ABOVE-ABOVE2111411020
Erythrocytes-UNKNOWN-BELOW0000100000
Erythrocytes-UNKNOWN-WITHIN1010122120
Erythrocytes-UNKNOWN-ABOVE0000000001
Erythrocytes-BELOW-BELOW6201342021
Erythrocytes-BELOW-WITHIN1001001020
Erythrocytes-WITHIN-UNKNOWN1000110001
Erythrocytes-WITHIN-BELOW3301231013
Erythrocytes-WITHIN-WITHIN83889192898389948992
Erythrocytes-WITHIN-ABOVE0000020000
Erythrocytes-ABOVE-WITHIN2111121000
Erythrocytes-ABOVE-ABOVE0020002211
Hemoglobin-UNKNOWN-BELOW0000200000
Hemoglobin-UNKNOWN-WITHIN1010022121
Hemoglobin-BELOW-BELOW7626365383
Hemoglobin-BELOW-WITHIN1211231011
Hemoglobin-WITHIN-UNKNOWN1000110001
Hemoglobin-WITHIN-BELOW5200311132
Hemoglobin-WITHIN-WITHIN81838986868289908291
Hemoglobin-WITHIN-ABOVE0010000000
Hemoglobin-ABOVE-WITHIN0112020100
Hemoglobin-ABOVE-ABOVE1001100110
Lymphocytes-UNKNOWN-WITHIN1010222121
Lymphocytes-BELOW-BELOW0002112004
Lymphocytes-BELOW-WITHIN2142311111
Lymphocytes-WITHIN-UNKNOWN1000110001
Lymphocytes-WITHIN-BELOW2001102101
Lymphocytes-WITHIN-WITHIN90918990889291949491
Lymphocytes-WITHIN-ABOVE0110100000
Lymphocytes-ABOVE-WITHIN1101000000
Lymphocytes-ABOVE-ABOVE0000100000
Monocytes-UNKNOWN-BELOW0000000010
Monocytes-UNKNOWN-WITHIN1010222111
Monocytes-BELOW-BELOW2000110113
Monocytes-BELOW-WITHIN3043354343
Monocytes-WITHIN-UNKNOWN1000110001
Monocytes-WITHIN-BELOW1232161313
Monocytes-WITHIN-WITHIN87928791908291888988
Monocytes-ABOVE-WITHIN1000000000
Monocytes-ABOVE-ABOVE1000000100
Neutrophils-UNKNOWN-WITHIN1010222121
Neutrophils-BELOW-BELOW1101020002
Neutrophils-BELOW-WITHIN1012112110
Neutrophils-WITHIN-UNKNOWN1000110001
Neutrophils-WITHIN-BELOW0131112042
Neutrophils-WITHIN-WITHIN92909090919092958992
Neutrophils-WITHIN-ABOVE1101200001
Neutrophils-ABOVE-WITHIN0100000010
Neutrophils-ABOVE-ABOVE0001000000
Platelets-UNKNOWN-UNKNOWN1000010000
Platelets-UNKNOWN-WITHIN2220225221
Platelets-BELOW-UNKNOWN0010000000
Platelets-BELOW-BELOW3011010102
Platelets-BELOW-WITHIN0110011010
Platelets-WITHIN-UNKNOWN1000111101
Platelets-WITHIN-BELOW0100111000
Platelets-WITHIN-WITHIN88898891928887908991
Platelets-WITHIN-ABOVE0112202131
Platelets-ABOVE-WITHIN1000011010
Platelets-ABOVE-ABOVE1012010213
Urea Nitrogen-UNKNOWN-WITHIN1001010120
Urea Nitrogen-UNKNOWN-ABOVE0000001000
Urea Nitrogen-BELOW-BELOW0001001000
Urea Nitrogen-BELOW-WITHIN0000001110
Urea Nitrogen-WITHIN-UNKNOWN0000000001
Urea Nitrogen-WITHIN-WITHIN91949391959491919197
Urea Nitrogen-WITHIN-ABOVE1001001111
Urea Nitrogen-ABOVE-WITHIN1021312220
Urea Nitrogen-ABOVE-ABOVE3001011100
Uric Acid-UNKNOWN-BELOW0000000010
Uric Acid-UNKNOWN-WITHIN1001010110
Uric Acid-UNKNOWN-ABOVE0000001000
Uric Acid-BELOW-BELOW1203014222
Uric Acid-BELOW-WITHIN1010000001
Uric Acid-WITHIN-UNKNOWN0000000001
Uric Acid-WITHIN-BELOW0110011103
Uric Acid-WITHIN-WITHIN91868789989192879183
Uric Acid-WITHIN-ABOVE0041000314
Uric Acid-ABOVE-WITHIN1212020214
Uric Acid-ABOVE-ABOVE2310010101
White Blood Cells-UNKNOWN-WITHIN1010222121
White Blood Cells-BELOW-BELOW2011101214
White Blood Cells-BELOW-WITHIN2023446221
White Blood Cells-WITHIN-UNKNOWN1000110001
White Blood Cells-WITHIN-BELOW3023321031
White Blood Cells-WITHIN-WITHIN86928986838888918890
White Blood Cells-WITHIN-ABOVE1001200101
White Blood Cells-ABOVE-WITHIN0101200010
White Blood Cells-ABOVE-ABOVE1101000000
PrimaryNumber of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination

A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

Time frame:
During a 30-day follow-up period (i.e., on the day of vaccination at Day 1, and 29 subsequent days) after first dose of vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After First Dose of Vaccination
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Any adverse event10001143717684
General adverse event10001132502344
Local adverse event00000021216340
PrimaryNumber of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination

A Grade 3 AE is any AE assessed as severe, i.e. which prevents normal, everyday activities. In adults, such an AE would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.

Time frame:
During a 30-day follow-up period (i.e., on the day of vaccination at Day 61, and 29 subsequent days) after second dose of vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Grade 3 Non-serious AEs (Solicited and Unsolicited) After Second Dose of Vaccination
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Any adverse event10001025358730
General adverse event10001024225510
Local adverse event00000001134220
PrimaryNumber of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

Time frame:
From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination
ParticipantsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Number of Subjects With Any Serious Adverse Events (SAEs) up to 30 Days After the Second Vaccination00006014211351
PrimaryNumber of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From first vaccination (Day 1) up to 30 days post second vaccination (Day 91)
Reported as:
Count of participants · Participants
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups)
ParticipantsLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days After the Second Vaccination (Part B Groups)0000000000
SecondaryNumber of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups

A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
From Day 1 up to the end of follow-up period (Month 14)
Reported as:
Count of participants · Participants
Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups
ParticipantsLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Number of Subjects With Any SAEs, up the End of Follow-up Period (Month 14) - Part B Groups133586119599
SecondaryNumber of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From Day 1 up to the end of follow-up period (Month 14)
Reported as:
Count of participants · Participants
Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups
ParticipantsLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Number of Subjects Reporting pIMDs up to the End of Follow-up Period (Month 14) - Part B Groups1000110001
SecondaryNumber of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups

The number of subjects with at least one RTI case was provided by group. Reported categories are RSV+ (= RTI episode tested as RSV positive by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on nasal/throat swab) and RSV- (= RTI episode tested as RSV negative by qRT-PCR on nasal/throat swab).

Time frame:
During the RSV season (from October 2019 to March 2020)
Reported as:
Count of participants · Participants
Number of Subjects With at Least One RSV-confirmed Respiratory Tract Infection (RTI) Episode Post-vaccination Reported During RTI Surveillance - Part B Groups
ParticipantsLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
RSV+1200000203
RSV-19122014172220161311
SecondaryHumoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A

Serological assays for the determination of functional antibodies against RSV-A were performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as geometric mean titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).

Time frame:
At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Reported as:
Geometric mean · Titers
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of Neutralizing Antibody Titers Against RSV-serotype A
TitersLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Day 11019 (634.6 to 1636.1)846.2 (481.7 to 1486.4)673.6 (325.3 to 1394.7)620.7 (365.1 to 1055.1)1015.5 (865 to 1192.2)1146.5 (931.6 to 1411)976.7 (837.7 to 1138.8)960.9 (801 to 1152.7)966.4 (822.9 to 1134.8)961.9 (809.5 to 1143)981.6 (832.7 to 1157.2)1023 (879.2 to 1190.2)1035.7 (864.5 to 1240.7)837.4 (701.3 to 999.9)
Day 317658.4 (4329.7 to 13546.2)11741.8 (4883.6 to 28231.5)8136.9 (5066.1 to 13069.1)789.1 (518.6 to 1200.9)5422.6 (4395 to 6690.5)7371 (5922.5 to 9173.8)9403.1 (7471.2 to 11834.4)5258.5 (4351.8 to 6354.1)6509.4 (5306.8 to 7984.4)9350.9 (7606 to 11496.1)6026.1 (4960.9 to 7320.1)6899.5 (5767.8 to 8253.2)8527.7 (7107.9 to 10231)751.7 (625.2 to 903.9)
Day 614659.8 (2090 to 10389.1)5895.8 (2791.9 to 12450.5)4761.5 (2687.7 to 8435.5)586.5 (333.1 to 1032.7)5657.9 (4736 to 6759.1)6490.8 (5190.3 to 8117.1)7907.4 (6253.9 to 9998.2)5019.4 (4281.5 to 5884.5)6201.9 (5106.3 to 7532.6)6681.7 (5498.4 to 8119.8)5048.9 (4184.4 to 6092)5902.1 (5023.4 to 6934.4)7201.4 (6000.4 to 8642.8)903.4 (750.8 to 1087.1)
Day 916237.8 (3648.1 to 10665.9)5457.5 (2532.9 to 11758.7)3651 (1949.6 to 6837.2)787.9 (495.5 to 1252.6)3936.2 (3281.9 to 4720.9)5632.1 (4559.2 to 6957.5)5956.1 (4881.4 to 7267.4)3924.7 (3266 to 4716.2)4770 (3904.6 to 5827.4)5175.5 (4273.1 to 6268.5)4435.9 (3654.7 to 5384.1)4850.5 (4096.8 to 5742.8)5980.6 (4988 to 7170.7)772.4 (646.2 to 923.3)
SecondaryHumoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations

The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect enzyme-linked immunosorbent assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).

Time frame:
At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Reported as:
Geometric mean · ELU/mL
Humoral Immune Response With Respect to Components of the Investigational Vaccine in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations
ELU/mLLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Day 18330.7 (5561.5 to 12478.9)7699.5 (5326 to 11130.8)7439.1 (5808.6 to 9527.2)6524.8 (4828.2 to 8817.6)7500.2 (6582.4 to 8545.9)7209.7 (6150.9 to 8450.7)7134.9 (6377.7 to 7982)6760.5 (5913.7 to 7728.5)7438 (6544.6 to 8453.4)6685.4 (5827 to 7670.4)7468.5 (6544 to 8523.5)7245.5 (6265.8 to 8378.3)6655.4 (5862.2 to 7555.9)6543.8 (5663 to 7561.6)
Day 3169843.3 (38345.8 to 127212.8)97848.5 (65057.1 to 147168)96645.4 (62880.7 to 148540.5)6601 (4888.4 to 8913.6)53994 (46566.7 to 62605.8)71618.4 (60729.6 to 84459.5)90933.2 (79096.2 to 104541.6)53598.9 (47062.7 to 61043)63823.4 (55601.6 to 73261)83462.5 (70906.1 to 98242.3)59026.1 (51236.4 to 68000)70524 (60825.4 to 81769.1)78831.2 (68382.5 to 90876.4)6593.4 (5672 to 7664.4)
Day 6150590.1 (27310.9 to 93711.7)58980.8 (38982.8 to 89237.7)56380.6 (38602.6 to 82346.1)6242.4 (4473 to 8711.7)47594.2 (41241.9 to 54924.8)56855.4 (47655.2 to 67831.7)70294.1 (61103.1 to 80867.5)41543.8 (36864.7 to 46816.8)51209.9 (44850.5 to 58470.9)62543.2 (52975.1 to 73839.3)45679.1 (39722.6 to 52528.7)54342.7 (47099 to 62700.5)61577.7 (53431.3 to 70966.1)6307.9 (5453.8 to 7295.9)
Day 9154900 (33635.4 to 89608.2)54884.7 (37768.6 to 79757.3)55444.4 (38128.6 to 80624)6246 (4375.8 to 8915.7)42523.7 (36905 to 48997.8)54711.2 (47013.5 to 63669.2)60955.2 (53029.7 to 70065.1)42504.6 (38044.3 to 47487.9)52846.4 (47105.8 to 59286.7)59624.5 (51680 to 68790.2)53779.9 (47588.5 to 60776.8)57314.9 (51038.1 to 64363.6)61433.7 (54066.2 to 69805)6748.7 (5804.1 to 7847.1)
SecondaryDescriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers

Among markers expressed were interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations. Reported statistics at each time point during which blood sample were collected for cell-mediated immunity, are geometric mean and inter-quartile range.

Time frame:
At pre-vaccination (Day 1), 30 days post-Dose 1 (Day 31), on the day of second vaccination (Day 61) and 30 days post-Dose 2 (Day 91)
Reported as:
Median · Cells per million CD4+ T Cells
Descriptive Statistics of the Frequency of RSVPreF3 Specific Cluster of Differentiation 4+ (CD4+) T Cells Expressing at Least 2 Markers
Cells per million CD4+ T CellsLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Day 1400.0 (348 to 791)272.0 (163 to 570)317.5 (184 to 628)393.0 (333 to 680)208.5 (84 to 351)166.0 (75 to 291)225.5 (109 to 327)209.5 (127 to 338)188.0 (103 to 326)192.0 (67 to 381)187.5 (91 to 325.5)185.0 (82 to 294)206.0 (98 to 351)178.0 (100.5 to 293.5)
Day 311649.0 (864 to 2604)2302.5 (1545 to 2725)1773.5 (1318 to 2124)303.0 (90 to 416)979.5 (639.5 to 1422.5)1089.5 (786 to 1812.5)1052.0 (674.5 to 1798)1594.0 (916 to 2360)1297.0 (881 to 2321)1466.0 (787 to 2116)1952.0 (1353 to 2953)1690.5 (1162.5 to 2691.5)1742.5 (1088 to 2360.5)176.0 (85 to 297)
Day 611271.0 (519 to 1679)1515.0 (1129 to 2159)1066.0 (764 to 1502)263.0 (184 to 459)688.0 (430 to 1076)737.0 (437 to 1309)770.0 (479 to 1235)1086.0 (663 to 1621)1020.0 (603 to 1405)934.0 (598 to 1517)1228.5 (777.5 to 1832.5)1315.0 (887 to 1728)1078.0 (781 to 1631)183.0 (61 to 311)
Day 911006.5 (872 to 1779)1221.0 (924 to 1518)1487.0 (1005 to 1664)374.5 (295 to 588)888.0 (650 to 1318)1034.0 (670 to 1598)1081.5 (769 to 1569)1732.0 (1163 to 2149)1603.5 (1087 to 2284)1496.0 (1179 to 2072)1966.0 (1339 to 2700)1558.0 (1263 to 2353)2096.5 (1441.5 to 2760.5)190.5 (100.5 to 308)

Adverse events

Collected over Solicited AEs were collected during the 7-day follow-up period after each vaccination. Unsolicited AEs were collected during the 30-day follow-up period after any vaccination. SAEs were collected during the whole study period, from Day 1 till Day 91 for Part A groups and till Month 14 for Part B groups.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose_PLAIN_A Group0/12 (0%)0/12 (0%)9/12 (75%)
Medium Dose_PLAIN_A Group0/12 (0%)0/12 (0%)10/12 (83.3%)
High Dose_PLAIN_A Group0/12 (0%)0/12 (0%)9/12 (75%)
Placebo_A Group0/12 (0%)0/12 (0%)10/12 (83.3%)
Low Dose_PLAIN_B Group0/101 (0%)13/101 (12.9%)62/101 (61.4%)
Medium Dose_PLAIN_B Group1/97 (1%)3/97 (3.1%)54/97 (55.7%)
High Dose_PLAIN_B Group1/100 (1%)5/100 (5%)61/100 (61%)
Low Dose_AS01E_B Group0/101 (0%)8/101 (7.9%)77/101 (76.2%)
Medium Dose_AS01E_B Group0/101 (0%)6/101 (5.9%)80/101 (79.2%)
High Dose_AS01E_B Group0/100 (0%)11/100 (11%)83/100 (83%)
Low Dose_AS01B_B Group1/103 (1%)9/103 (8.7%)91/103 (88.3%)
Medium Dose_AS01B_B Group0/100 (0%)5/100 (5%)88/100 (88%)
High Dose_AS01B_B Group1/101 (1%)9/101 (8.9%)93/101 (92.1%)
Placebo_B Group0/101 (0%)9/101 (8.9%)54/101 (53.5%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/120/120/120/121/1010/970/1000/1010/1011/1000/1032/1000/1010/101
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/120/120/120/121/1010/970/1001/1012/1010/1000/1030/1000/1011/101
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/120/120/120/121/1010/970/1002/1010/1010/1001/1030/1001/1010/101
Back painMusculoskeletal and connective tissue disorders0/120/120/120/121/1010/971/1000/1010/1010/1002/1030/1000/1010/101
Cardio-respiratory arrestCardiac disorders0/120/120/120/120/1011/970/1000/1010/1010/1000/1030/1000/1010/101
DeathGeneral disorders0/120/120/120/120/1011/971/1000/1010/1010/1001/1030/1001/1010/101
Patella fractureInjury, poisoning and procedural complications0/120/120/120/120/1011/970/1000/1010/1010/1000/1030/1000/1010/101
Ischaemic strokeNervous system disorders0/120/120/120/120/1011/970/1000/1010/1010/1000/1030/1000/1010/101
Aortic aneurysm ruptureVascular disorders0/120/120/120/120/1011/970/1000/1010/1010/1000/1030/1000/1010/101
Shock haemorrhagicVascular disorders0/120/120/120/120/1011/970/1000/1010/1010/1000/1030/1000/1010/101
Most frequent other events
Showing 10 of 233
Most frequent other events
EventLow Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B Group
Injection site painGeneral disorders6/129/128/121/1223/10119/9731/10060/10163/10165/10081/10378/10082/1018/101
FatigueGeneral disorders5/125/124/127/1229/10120/9729/10041/10139/10136/10045/10347/10053/10124/101
HeadacheNervous system disorders3/125/125/125/1216/10114/9717/10028/10125/10124/10045/10338/10038/10113/101
MyalgiaMusculoskeletal and connective tissue disorders0/121/121/120/125/1016/975/10014/10112/10115/10028/10322/10032/1019/101
ArthralgiaMusculoskeletal and connective tissue disorders0/120/120/120/129/1018/974/10014/10119/10118/10028/10319/10024/10111/101
Gastrointestinal disorderGastrointestinal disorders2/122/122/123/1211/1019/9714/10013/10111/10115/10018/10312/10019/10113/101
Upper respiratory tract infectionInfections and infestations0/121/121/123/123/1013/974/1003/1014/1013/1004/1032/1006/1012/101
ErythemaSkin and subcutaneous tissue disorders0/121/120/120/121/1011/974/1007/1019/10114/10024/10320/10024/1011/101
ChillsGeneral disorders0/122/120/121/122/1011/972/10011/1017/1016/10021/10319/10019/1013/101
Injection site swellingGeneral disorders0/120/120/120/120/1011/974/1008/1019/10111/10017/1039/10014/1010/101

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Low Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B GroupTotal
Mean31.2 ± 7.026.5 ± 4.029.9 ± 6.131.6 ± 5.667.3 ± 5.667.8 ± 5.667.9 ± 4.967.8 ± 5.167.1 ± 5.667.6 ± 5.267.6 ± 4.967.5 ± 4.967.5 ± 4.968.1 ± 5.765.9 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B GroupTotal
Female877958545758575759585758604
Male455343434343444344424443449
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Dose_PLAIN_A GroupMedium Dose_PLAIN_A GroupHigh Dose_PLAIN_A GroupPlacebo_A GroupLow Dose_PLAIN_B GroupMedium Dose_PLAIN_B GroupHigh Dose_PLAIN_B GroupLow Dose_AS01E_B GroupMedium Dose_AS01E_B GroupHigh Dose_AS01E_B GroupLow Dose_AS01B_B GroupMedium Dose_AS01B_B GroupHigh Dose_AS01B_B GroupPlacebo_B GroupTotal
AMERICAN INDIAN OR ALASKA NATIVE000010000100002
ASIAN010000010000103
BLACK OR AFRICAN AMERICAN212157412751177475
OTHER000000300100105
WHITE1010101195909388949392939297968
08

Study locations

21 sites
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Elkridge, Maryland 21075, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    Omaha, Nebraska 68134, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Hickory, North Carolina 28602, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Fort Worth, Texas 76135, United States
  • GSK Investigational Site
    Houston, Texas 77081, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Wilrijk, 2610, Belgium
09

References and documents

Publications

  • Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, Vanden Abeele C, Collete D, de Heusch M, Salaun B, De Schrevel N, Koch J, Verheust C, Dezutter N, Struyf F, Mesaros N, Tica J, Hulstrom V. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. J Infect Dis. 2023 Mar 28;227(6):761-772. doi: 10.1093/infdis/jiac327. PubMed 35904987 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Dec 2019, 10 months.

Results were first posted in Mar 2022, 2 years 3 months after primary completion. A results delay was requested in Dec 2020.

Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2019
First posted
Jan 24, 2019
StartActual
Jan 21, 2019
Primary completionActual
Dec 12, 2019
CompletionActual
Nov 30, 2020
Results delay requested
Dec 11, 2020
Results first posted
Mar 23, 2022
Last update
Aug 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03814590
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 24, 2019
Start date
Jan 21, 2019
Primary completion
Dec 12, 2019
Completion
Nov 30, 2020
Results posted
Mar 23, 2022
Last update
Aug 5, 2022

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion